NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Biotech firm Novavax dropped 9.1% after cutting its annual revenue forecast due to lower-than-expected sales of its COVID-19 ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

The Pfizer and Moderna shots are formulated against a virus subtype called KP.2 while the Novavax vaccine targets its parent ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax shares fell after the vaccine developer cut its full-year growth projections, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. Write to Rob Curran at ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

The FDA concluded that the event was not related to the vaccine. Robert Walker, MD, chief medical officer at Novavax, thanked ...

The FDA concluded that the event was not related to the vaccine. Robert Walker, MD, chief medical officer at Novavax, thanked ...

Novavax's stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year ...